aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Globe Newswire•24/09/2026•06:00 ET
0
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.
Company expects to initiate study-related activities in the fourth quarter of 2026.
Get started
Create a free account to read the full story and Whiz Insights.